The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Genetic alterations in bladder cancer
Abstract
To see whether genetic alterations follow a sequence of events leading to bladder cancer progression, 60 paired bladder tumours and normal tissues were analysed with polymorphic DNA markers, correlating loss of heterozygosity (LOH) at candidate tumour suppressor gene sites with pathological indices of poor clinical outcome. Distinct genotypic patterns were associated with early and late stages of bladder cancer. 9q deletions were observed in all superficial papillary tumours (Ta) and almost all tumours invading the lamina propria (T1), suggesting that this event associates with the development of superficial bladder tumours. However, 3p, 5q, and 17p deletions were absent in the Ta tumours but were identified in invasive bladder cancers. Two genetic pathways characterise the evolution of superficial bladder tumours. 9qLOH was detected in most Ta tumours, but in only 43% of muscle invasive neoplasms. Our hypothesis is that certain chromosomal abnormalities have a defined role in bladder tumour development, whereas others correlate with pathological indices of poor clinical outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Mad2 was significantly increased in many bladder carcinomas when compared to normal urothelium (data not shown), particularly in the more advanced tumours, where Rb inactivation is common 19 (Fig. 3a, middle panels).”
From Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control (2004) · cites this paper as [19]
In the citing paper
“particularly in the more advanced tumours, where Rb inactivation is common 19”
From Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control (2004) · cites this paper as [19]
Citations
Cites
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,331
Allelotype of Colorectal Carcinomas
Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., & White, R. L. (1989) · Science · doi:10.1126/science.2565047 · Cited by 1,302
Location of gene for Gorlin syndrome
Farndon, P. A., Mastro, R. G. D., Kilpatrick, M. W., & Evans, D. G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90868-4 · Cited by 397
Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer
Cordon‐Cardo, C., Wartinger, D. D., Petrylak, D. P., Dalbagni, G. M., Fair, W. R., FUKS, Z. Y., & Reuter, V. E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1251 · Cited by 334
Self-citationLogothetis, C. J., Xu, H., Ro, J. Y., Hu, S., Şahin, A., Ordóǹez, N. G., & Benedict, W. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1256 · Cited by 244
Molecular genetic alterations in superficial and locally advanced human bladder cancer.
Presti, J. C., Reuter, V. E., Galan, T. I., Fair, W. R., & Cordón-Cardó, C. (1991) · PubMed · Cited by 230
Self-citationDevilee, P., van Vliet, M., van Sloun, P., Kuipers‐Dijkshoorn, N. J., Hermans, J., Pearson, P. L., & Cj, C. (1991) · PubMed · Cited by 195
Cytogenetic Studies of Carcinoma in Situ of the Bladder: Prognostic Implications
Tyrkus, M., Powell, I. J., & Fakr, W. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)36504-7 · Cited by 38
Cited by
Sorted by citations
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1697 · Cited by 696
Two molecular pathways to transitional cell carcinoma of the bladder.
Spruck, C., Ohneseit, P. F., Gonzalez‐Zulueta, M., Esrig, D., Miyao, N., Tsai, Y., Lerner, S. P., Schmütte, C., Yang, A. S., & Cote, R. (1994) · PubMed · Cited by 601
Hernando, E., Nahlé, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., Michel, L., Mittal, V., Gerald, W., Benezra, R., et al. (2004) · Nature · doi:10.1038/nature02820 · Cited by 562
Self-citationSänchez‐Carbayo, M., Socci, N. D., Lozano, J., Saint, F., & Cordon‐Cardo, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2375 · Cited by 549
Self-citationMutations of cell cycle regulators. Biological and clinical implications for human neoplasia.
Cordon‐Cardo, C. (1995) · PubMed Central · Cited by 527
Self-citation
Metadata
- Authors
- Dalbagni, G., Presti, J., Fair, W. R., Reuter, V., & Cordon-Cardo, C.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1993-08
- Volume
- 342
- Issue
- 8869
- Pages
- 469-471
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2039609330
- Cited by
- 238
- References
- 9
- Citations by year
- 2025: 1 · 2024: 4 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 7
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (NCI CA-47538)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- bladder cancer, loss of heterozygosity, tumor suppressor, 9q deletion, muscle-invasive bladder cancer, tumor progression, chromosomal abnormalities, 3p deletion, 5q deletion, 17p deletion, clinical outcomes
- MeSH terms
- Alleles, Urinary Bladder Neoplasms, Chromosome Deletion, Chromosomes, Human, Pair 13, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 3, Chromosomes, Human, Pair 5, Chromosomes, Human, Pair 9, Genotype, Heterozygote, Humans, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Genes, Tumor Suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
